Skip to main content

Diabetes and Metabolism

The Diabetes and Metabolism Research Group is search is lead by Dr. Rafael Simó (Hirsch index:54), Head of the Endocrinology Department, Professor of Medicine & Endocrinology at UAB and current President of the European Association for the Study of Diabetes-Eye Complications. The group consists of 7 senior clinical investigators, 4 basic post-doctoral researchers, 4 pre-doc researchers, 3 laboratory technicians and one coordinator of clinical assays.  

The group belongs to “CIBER” of Diabetes and Associated Metabolic Diseases (CIBERDEM. ISCIII) and has been recognized as consolidated group by the Generalitat de Catalunya (AQU/AGAUR).

Since 2014 this group has been qualified as outstanding in the evaluations performed by the ANEP, CIBERDEM and the external Scientific Advisory Board of VHIR. 

The main lines of research are:

  • Complications of diabetes (in particular diabetic retinopathy)
  • Obesity and its co-morbidities
  • Type 2 diabetes and cognitive impairment
  • Thyroid diseases
  • Hospital Nutrition. 

Projects

Plataforma ISCIII de soporte para la Investigación Clínica

IP: Inmaculada Fuentes Camps
Collaborators: Gemma Vona Giralt, Antonio Moreno Galdó, Rafael Simó Canonge, Núria Pérez Picazo, Tamara Del Rio Higueras, Ariadna Martín Balcells, Olga Sánchez- Maroto Carrizo, Angelica Valderrama Rodríguez, Joan Genescà Ferrer, Paula Isabel Roldan Caballero
Funding agency: Instituto de Salud Carlos III
Funding: 315150
Reference: PT20/00078
Duration: 01/01/2021 - 31/12/2024

Desentrañando las vías protectoras de los SGLT2i y GLP-1RA en la enfermedad renal diabética: papel de las proteínas adaptadoras MAP17 y D-AKAP-2 en ratones db/db y organoides renales humanos.

IP: Maria Jose Soler Romeo
Collaborators: Mario Alonso Narvaez Barros, Pamela Dominguez Baez, Sheila Bermejo Garcia, Alejandra Planas Vilaseca, Concepció Jacobs Cachá, Juan Carlos León Román, Irene Martinez Diaz
Funding agency: Instituto de Salud Carlos III
Funding: 122210
Reference: PI21/01292
Duration: 01/01/2022 - 30/06/2026

Blog

News

The European project, in which Vall d'Hebron participates, will favor personalized diagnosis and innovative therapeutic strategies in patients with the disease.

This investment from EIT Health in the project will enable D-Sight to progress in the clinical development of its groundbreaking treatment for the early stages of diabetic retinopathy.

This initiative of the ”la Caixa” Foundation offers the selected entrepreneurial scientists financial support and support through individual mentoring and training.